


Financial / Non-Financial Highlights

(For the fiscal years as of / ended March 31)

Financial Highlights


Revenue 6% UP (YoY) ▲



Revenue rose 6% year on year as a result of positive growth in the gastrointestinal endoscope, surgical device, and endotherapy device fields of the Medical Business.

Operating Profit 14% UP (YoY) ▲


Operating Margin 0.7 point UP (YoY) ▲



Regardless of an operating loss in the Imaging Business attributable to one-time expenses incurred due to the reorganization of production bases, operating profit increased 14% year on year because of the benefits of yen depreciation. In addition, the operating margin was up 0.7 percentage point.

EBITDA 7% UP (YoY) ▲


EBITDA Margin 0.1 point UP (YoY) ▲



Earnings before interest, taxes, depreciation, and amortization (EBITDA) increased 7% year on year primarily as a result of the rise in operating profit. The EBITDA margin was 17.0%.

Profit (Loss) Attributable to Owners of Parent 33% UP (YoY) ▲


ROE 2.3 points UP (YoY) ▲



Profit attributable to owners of parent was up 33% year on year due to lower interest paid following a reduction in interest-bearing debt. ROE rose 2.3 percentage points, to 13.6%.


Total Equity 12% UP (YoY) ▲

Ratio of Equity Attributable to Owners of Parent to Total Assets 4.1 points UP (YoY) ▲



The ratio of equity attributable to owners of parent to total assets rose 4.1 percentage points due to higher retained earnings stemming from the recording of profit attributable to owners of parent of ¥57.1 billion as well as reduced interest-bearing debt.


Free Cash Flow ¥39.4 billion DOWN (YoY) ▼



Net cash provided by operating activities amounted to ¥95.1 billion, and positive free cash flow of ¥41.8 billion was recorded as a result of outflows related to the acquisition of Image Stream Medical, Inc.

Basic Earnings (Loss) per Share ¥41.83 UP (YoY) ▲


Equity Attributable to Owners of Parent per Share* ¥143.56 UP (YoY) ▲



Basic earnings per share amounted to ¥166.84 as profit attributable to owners of parent of ¥57.1 billion was recorded. Equity attributable to owners of parent per share increased ¥143.56 year on year.


Annual Dividends per Share — (YoY) ➡

Payout Ratio 5.6 points DOWN (YoY) ▼




Annual dividends per share were ¥28, the same level as in fiscal 2017. The dividend payout ratio was 16.8%. (The total return ratio was 23.2%.)

* "Total equity per share" under Japanese GAAP




R&D expenditures were conducted in fields demonstrating growth potential, primarily in the Medical Business. One investment target was the ORBEYE surgical microscope system equipped with 4K and 3D video technologies that was launched in certain regions in October 2017. We conduct investments targeting a ratio of R&D expenditures to revenue of between 9% and 10%.




Capital expenditures rose as a result of investments in the redevelopment of gastrointestinal endoscope product factories in Europe and the construction of a training and service center in South Korea. Depreciation and amortization was relatively unchanged year on year.


Non-Financial Highlights




The majority of the energy consumed by Olympus is in the form of electricity. In order to reduce electricity use, we are promoting energy-saving activities in daily operations, utilizing renewable energy, introducing energy-saving equipment, and developing manufacturing technologies that use less energy and resources. In this manner, the Company is working to reduce the environmental impact of its manufacturing operations.



Olympus is working to reduce CO₂ emissions from logistics by lowering transportation loads through the reduction of product and packaging weights, improving transportation efficiency, and accelerating the modal shift toward transportation methods that produce less CO₂.



Olympus uses water to wash product components. To reduce water use, the Company is continuously developing production methods that require less water and inspecting equipment to prevent leakage. We are also working to minimize the environmental impact by monitoring wastewater treatment facilities and conducting appropriate maintenance and by managing the quality of wastewater.



Olympus continues to pursue higher resource productivity in its manufacturing activities through efforts at various levels. These efforts include reduction in disposal at landfills, the improvement of recycling ratios, the reduction of processing losses, and the design of products to minimize waste.

*1 Scope: Olympus Corporation and its domestic and overseas subsidiaries (excluding those of small scale)

*2 Olympus reports in the following categories under the GHG Protocol.

Scope 1: Greenhouse gas emissions resulting from the direct use of fossil fuels

Scope 2: Greenhouse gas emissions resulting from secondary utilization, such as the purchase of electric power